Assessment of Immediate Allergic Reactions After Immunization With the Pfizer BNT162b2 Vaccine Using Intradermal Skin Testing With the COVID-19 Vaccines

Overview

Journal J Allergy Clin Immunol Pract

Specialty Allergy & Immunology

Date 2022 Aug 16

PMID 35973526

Authors

Ronen Shavit

Ramit Maoz-Segal

Irena Offengenden

Soad Haj Yahia

Diti Machnes Maayan

Yulia Lifshitz

Stanley Niznik

Michal Deutch

Eti Elbaz

Hosney Genaim

Mona Iancovici-Kidon

Nancy Agmon-Levin

Affiliations

Soon will be listed here.

Abstract

Background: Allergic reactions to the coronavirus disease 2019 (COVID-19) vaccines have raised concerns, particularly as repeated doses are required. Skin tests with the vaccines excipient were found to be of low value, whereas the utility of skin tests with the whole vaccine is yet to be determined.

Objective: To evaluate a panel of skin tests and the outcomes of subsequent doses of immunization among subjects who suffered an immediate allergic reaction to the BioNTech (BNT162b2) COVID-19 vaccine.

Methods: Between March and December 2021, patients who experienced symptoms consistent with immediate allergic reactions to the BNT162b2 vaccine and were referred to the Sheba Medical Center underwent skin testing with polyethylene glyol (PEG)-containing medicines, Pfizer-BNT162b2, and Oxford-AstraZeneca vaccine (AZD1222). Further immunization was performed accordingly and under medical observation.

Results: A total of 51 patients underwent skin testing for suspected allergy to the COVID vaccines, of which 38 of 51 (74.5%) were nonreactive, 7 of 51(13.7%) had no skin sensitization but suffered a clinical reaction during skin testing (mainly cough), and 6 of 51 (11.7%) exhibited immediate skin sensitization. Both skin sensitization and cough during testing were related to a higher use of adrenaline following immunization (P = .08 and P = .024, respectively). Further immunization with the BNT162b2 vaccine was recommended unless sensitization or severe reaction to previous immunization was evident. The latter were referred to be tested/receive the alternative AZD1222 vaccine. Ten patients underwent skin testing with AZD1222: 2 of 10 (20%) demonstrated skin sensitization to both vaccines; thus, 8 of 10 were immunized with the AZD1222, of which 2 of 8 (25%) had allergic reactions.

Conclusions: Immediate allergic reactions to COVID-19 vaccines are rare but can be severe and reoccur. Intradermal testing with the whole vaccine may discriminate sensitized subjects, detect cross-sensitization between vaccines, and enable estimation of patients at higher risk.

Citing Articles

Challenges in diagnosing polyethylene glycol and polysorbate 80 allergies: implications for allergic reactions in COVID-19 mRNA vaccination program: experience from Qatar.

Aqel S, Thalappil S, Imameldin A, Mudawi D, Al Maslamani M, Al-Khal A Front Allergy. 2025; 5():1502285.

PMID: 39845650 PMC: 11753240. DOI: 10.3389/falgy.2024.1502285.

Study of Excipients in Delayed Skin Reactions to mRNA Vaccines: Positive Delayed Intradermal Reactions to Polyethylene Glycol Provide New Insights for COVID-19 Arm.

Pesque D, Pujol R, Marcantonio O, Vidal-Navarro A, Ramada J, Arderiu-Formenti A Vaccines (Basel). 2022; 10(12).

PMID: 36560458 PMC: 9788122. DOI: 10.3390/vaccines10122048.

SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers.

Golshani M, Svobodova L, Stepanek L, Zeman J, Nytrova P, Posova H Vaccines (Basel). 2022; 10(12).

PMID: 36560450 PMC: 9782529. DOI: 10.3390/vaccines10122038.

Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy).

Larese Filon F, Lazzarato I, Patriarca E, Iavernig T, Peratoner A, Perri G Vaccines (Basel). 2022; 10(10).

PMID: 36298481 PMC: 9607499. DOI: 10.3390/vaccines10101616.

References

Warren C, Snow T, Lee A, Shah M, Heider A, Blomkalns A . Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open. 2021; 4(9):e2125524. PMC: 8449279. DOI: 10.1001/jamanetworkopen.2021.25524. View

Stone Jr C, Liu Y, Relling M, Krantz M, Pratt A, Abreo A . Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol Pract. 2018; 7(5):1533-1540.e8. PMC: 6706272. DOI: 10.1016/j.jaip.2018.12.003. View

Klein N, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson K . Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021; 326(14):1390-1399. PMC: 8511971. DOI: 10.1001/jama.2021.15072. View

Thong B, Tan T . Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011; 71(5):684-700. PMC: 3093074. DOI: 10.1111/j.1365-2125.2010.03774.x. View

Broyles A, Banerji A, Barmettler S, Biggs C, Blumenthal K, Brennan P . Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. J Allergy Clin Immunol Pract. 2020; 8(9S):S16-S116. DOI: 10.1016/j.jaip.2020.08.006. View

Cabanillas B, Novak N . Allergy to COVID-19 vaccines: A current update. Allergol Int. 2021; 70(3):313-318. PMC: 8062405. DOI: 10.1016/j.alit.2021.04.003. View

Wolfson A, Robinson L, Li L, McMahon A, Cogan A, Fu X . First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. J Allergy Clin Immunol Pract. 2021; 9(9):3308-3320.e3. PMC: 8217699. DOI: 10.1016/j.jaip.2021.06.010. View

Sellaturay P, Nasser S, Ewan P . Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis). J Allergy Clin Immunol Pract. 2020; 9(2):670-675. DOI: 10.1016/j.jaip.2020.09.029. View

Mustafa S, Ramsey A, Staicu M . Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports. Ann Intern Med. 2021; 174(8):1177-1178. PMC: 8033634. DOI: 10.7326/L21-0104. View

10.

Kaur R, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P . Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem. 2021; 36(4):427-439. PMC: 7997788. DOI: 10.1007/s12291-021-00968-z. View

11.

Blumenthal K, Robinson L, Camargo Jr C, Shenoy E, Banerji A, Landman A . Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA. 2021; 325(15):1562-1565. PMC: 7941251. DOI: 10.1001/jama.2021.3976. View

12.

Behera S, Das S, Chengappa K, Xavier A, Selvarajan S . Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity. Curr Clin Pharmacol. 2018; 14(2):84-90. PMC: 7011677. DOI: 10.2174/1574884713666181112125714. View

13.

Garvey L, Nasser S . Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?. Br J Anaesth. 2021; 126(3):e106-e108. PMC: 7834677. DOI: 10.1016/j.bja.2020.12.020. View

14.

Shimabukuro T, Cole M, Su J . Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021; 325(11):1101-1102. PMC: 8890485. DOI: 10.1001/jama.2021.1967. View

15.

Anand P, Stahel V . Review the safety of Covid-19 mRNA vaccines: a review. Patient Saf Surg. 2021; 15(1):20. PMC: 8087878. DOI: 10.1186/s13037-021-00291-9. View

16.

Cabanillas B, Akdis C, Novak N . Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?. Allergy. 2020; 76(6):1617-1618. DOI: 10.1111/all.14711. View

17.

Marcelino J, Farinha S, Silva R, Didenko I, Proenca M, Tomaz E . Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine. J Allergy Clin Immunol Pract. 2021; 9(6):2476-2477. PMC: 7985655. DOI: 10.1016/j.jaip.2021.03.022. View

18.

Pitlick M, Sitek A, DNetto M, Dages K, Chiarella S, Gonzalez-Estrada A . Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions. Ann Allergy Asthma Immunol. 2021; 128(2):153-160. PMC: 8594060. DOI: 10.1016/j.anai.2021.11.006. View

19.

Kolahchi Z, De Domenico M, Uddin L, Cauda V, Grossmann I, Lacasa L . COVID-19 and Its Global Economic Impact. Adv Exp Med Biol. 2021; 1318:825-837. DOI: 10.1007/978-3-030-63761-3_46. View

20.

Shimabukuro T, Nair N . Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA. 2021; 325(8):780-781. PMC: 8892260. DOI: 10.1001/jama.2021.0600. View